Paediatric Subanalysis of TSUBASA, Assessing Physical Activity, Bleeding, Quality of Life and Safety in People with Haemophilia A Receiving Emicizumab
Children and adolescents with HA who receive prophylaxis with emicizumab may be able to engage in consistent physical activity, with a low risk of experiencing bleeds. Additionally, the questionnaire responses from caregivers on physical activity and caregiver experience provide rare insights into the real-world impact of emicizumab prophylaxis. These findings present a more comprehensive view of the benefits of emicizumab. No new safety signals were observed and QoL was maintained for 2 years after emicizumab initiation.
Authors
- Tomomi Shimura
- Chiai Nagae
- Azusa Nagao (ORCID: https://orcid.org/0000-0002-1126-1498)
- Kagehiro Amano (ORCID: https://orcid.org/0000-0003-3186-7267)
- Masanori Nojima (ORCID: https://orcid.org/0000-0002-8788-2522)
- Nobuaki Suzuki (ORCID: https://orcid.org/0000-0003-2250-7964)
- Yoshimasa Sugao
- Mika Kawano
- Akihiro SAWADA
- Keiji NOGAMI
- Teruhisa Fujii
Institutions
- Kansai Medical University (JP)
- Tokyo Medical University (JP)
- Tokyo University of Science (JP)
- St. Marianna University School of Medicine (JP)
- Nagoya University Hospital (JP)
- Ogikubo Hospital (JP)
- Chugai Pharma (United States) (US)
- Hiroshima University Hospital (JP)
- Nara Medical University (JP)
- Hyogo University (JP)
Publication Details
- Journal
- TH Open
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1055/a-2781-8278
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chugai Pharmaceutical